BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tatham LM, Rannard SP, Owen A. Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics. Ther Deliv 2015;6:469-90. [PMID: 25996045 DOI: 10.4155/tde.15.4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Sonti S, Sharma AL, Tyagi M. HIV-1 persistence in the CNS: Mechanisms of latency, pathogenesis and an update on eradication strategies. Virus Res 2021;303:198523. [PMID: 34314771 DOI: 10.1016/j.virusres.2021.198523] [Reference Citation Analysis]
2 Owen A, Rannard S. Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy. Adv Drug Deliv Rev 2016;103:144-56. [PMID: 26916628 DOI: 10.1016/j.addr.2016.02.003] [Cited by in Crossref: 81] [Cited by in F6Publishing: 78] [Article Influence: 13.5] [Reference Citation Analysis]
3 Aljbour ND. Enhanced Oral Bioavailability through Nanotechnology in Saudi Arabia: A Meta-Analysis. Arabian Journal of Chemistry 2022. [DOI: 10.1016/j.arabjc.2022.103715] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Owen A, Rannard S. Considerations for clinically-relevant nanomedicine therapies for chronic diseases. Nanomedicine (Lond) 2015;10:3103-7. [PMID: 26446297 DOI: 10.2217/nnm.15.135] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
5 Gong Y, Chowdhury P, Midde NM, Rahman MA, Yallapu MM, Kumar S. Novel elvitegravir nanoformulation approach to suppress the viral load in HIV-infected macrophages. Biochem Biophys Rep 2017;12:214-9. [PMID: 29214223 DOI: 10.1016/j.bbrep.2017.10.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
6 Sosnik A, Augustine R. Challenges in oral drug delivery of antiretrovirals and the innovative strategies to overcome them. Adv Drug Deliv Rev 2016;103:105-20. [PMID: 26772138 DOI: 10.1016/j.addr.2015.12.022] [Cited by in Crossref: 59] [Cited by in F6Publishing: 49] [Article Influence: 9.8] [Reference Citation Analysis]
7 Kigen G, Edwards G. Enhancement of saquinavir absorption and accumulation through the formation of solid drug nanoparticles. BMC Pharmacol Toxicol 2018;19:79. [PMID: 30509316 DOI: 10.1186/s40360-018-0275-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Kermanizadeh A, Powell LG, Stone V, Møller P. Nanodelivery systems and stabilized solid-drug nanoparticles for orally administered medicine: current landscape. Int J Nanomedicine 2018;13:7575-605. [PMID: 30510419 DOI: 10.2147/IJN.S177418] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
9 Rudzińska M, Daglioglu C, Savvateeva LV, Kaci FN, Antoine R, Zamyatnin AA Jr. Current Status and Perspectives of Protease Inhibitors and Their Combination with Nanosized Drug Delivery Systems for Targeted Cancer Therapy. Drug Des Devel Ther 2021;15:9-20. [PMID: 33442233 DOI: 10.2147/DDDT.S285852] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
10 Surve DH, Jindal AB. Recent advances in long-acting nanoformulations for delivery of antiretroviral drugs. J Control Release 2020;324:379-404. [PMID: 32461114 DOI: 10.1016/j.jconrel.2020.05.022] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
11 El-Far AH, Godugu K, Salaheldin TA, Darwish NHE, Saddiq AA, Mousa SA. Nanonutraceuticals: Anti-Cancer Activity and Improved Safety of Chemotherapy by Costunolide and Its Nanoformulation against Colon and Breast Cancer. Biomedicines 2021;9:990. [PMID: 34440193 DOI: 10.3390/biomedicines9080990] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Hobson JJ, Owen A, Rannard SP. The potential value of nanomedicine and novel oral dosage forms in the treatment of HIV. Nanomedicine 2018;13:1963-5. [DOI: 10.2217/nnm-2018-0182] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Gendelman HE, McMillan J, Bade AN, Edagwa B, Kevadiya BD. The Promise of Long-Acting Antiretroviral Therapies: From Need to Manufacture. Trends Microbiol 2019;27:593-606. [PMID: 30981593 DOI: 10.1016/j.tim.2019.02.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
14 Nabi B, Rehman S, Baboota S, Ali J. Insights on Oral Drug Delivery of Lipid Nanocarriers: a Win-Win Solution for Augmenting Bioavailability of Antiretroviral Drugs. AAPS PharmSciTech 2019;20:60. [PMID: 30623263 DOI: 10.1208/s12249-018-1284-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
15 Rudrapal M, Celik I, Chinnam S, Azam Ansari M, Khan J, Alghamdi S, Almehmadi M, Zothantluanga JH, Khairnar SJ. Phytocompounds as potential inhibitors of SARS-CoV-2 Mpro and PLpro through computational studies. Saudi Journal of Biological Sciences 2022. [DOI: 10.1016/j.sjbs.2022.02.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Osborne O, Peyravian N, Nair M, Daunert S, Toborek M. The Paradox of HIV Blood-Brain Barrier Penetrance and Antiretroviral Drug Delivery Deficiencies. Trends Neurosci 2020;43:695-708. [PMID: 32682564 DOI: 10.1016/j.tins.2020.06.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
17 Curley P, Liptrott NJ, Owen A. Advances in nanomedicine drug delivery applications for HIV therapy. Future Sci OA 2018;4:FSO230. [PMID: 29255619 DOI: 10.4155/fsoa-2017-0069] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
18 Savage AC, Tatham LM, Siccardi M, Scott T, Vourvahis M, Clark A, Rannard SP, Owen A. Improving maraviroc oral bioavailability by formation of solid drug nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics 2019;138:30-6. [DOI: 10.1016/j.ejpb.2018.05.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
19 Faria MJ, Lopes CM, das Neves J, Lúcio M. Lipid Nanocarriers for Anti-HIV Therapeutics: A Focus on Physicochemical Properties and Biotechnological Advances. Pharmaceutics 2021;13:1294. [PMID: 34452255 DOI: 10.3390/pharmaceutics13081294] [Reference Citation Analysis]
20 Vinothini K, Rajan M. Mechanism for the Nano-Based Drug Delivery System. Characterization and Biology of Nanomaterials for Drug Delivery. Elsevier; 2019. pp. 219-63. [DOI: 10.1016/b978-0-12-814031-4.00009-x] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
21 Sanjay ST, Zhou W, Dou M, Tavakoli H, Ma L, Xu F, Li X. Recent advances of controlled drug delivery using microfluidic platforms. Adv Drug Deliv Rev 2018;128:3-28. [PMID: 28919029 DOI: 10.1016/j.addr.2017.09.013] [Cited by in Crossref: 137] [Cited by in F6Publishing: 108] [Article Influence: 34.3] [Reference Citation Analysis]
22 Bezerra-Souza A, Fernandez-Garcia R, Rodrigues GF, Bolas-Fernandez F, Dalastra Laurenti M, Passero LF, Lalatsa A, Serrano DR. Repurposing Butenafine as An Oral Nanomedicine for Visceral Leishmaniasis. Pharmaceutics 2019;11:E353. [PMID: 31330776 DOI: 10.3390/pharmaceutics11070353] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
23 Nguyen TT, Nguyen BP, Nguyen DTD, Nguyen NH, Nguyen DH, Nguyen CK. Retrovirus Drugs-Loaded PEGylated PAMAM for Prolonging Drug Release and Enhancing Efficiency in HIV Treatment. Polymers (Basel) 2021;14:114. [PMID: 35012136 DOI: 10.3390/polym14010114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Elkateb H, Tatham LM, Cauldbeck H, Niezabitowska E, Owen A, Rannard S, McDonald T. Optimization of the synthetic parameters of lipid polymer hybrid nanoparticles dual loaded with darunavir and ritonavir for the treatment of HIV. Int J Pharm 2020;588:119794. [PMID: 32828978 DOI: 10.1016/j.ijpharm.2020.119794] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Puoti M, Rossotti R, Baiguera C, Orso M. Treatment of hepatitis C virus genotype 1-infected patients: mission accomplished? Liver Int 2016;36:181-4. [DOI: 10.1111/liv.13040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]